Johnson & Johnson (JNJ) is expected to disclose its Q2 earnings reports on July 17, where the current expectation is $22.38 billion in revenue and earnings of $2.71 per share.
JNJ Revenue Segment Analysis
The healthcare segment maintained an upbeat expectation, surpassing them in the last four quarters with an average surprise of 4.09%. Overall, JNJ surpassed expectations by 2.65% in the most recent quarter.
According to analysts' forecasts, Stelara sales could come at $2.85 billion, while their model anticipates $2.76 billion. The consensus for Darzalex is $2.89 billion, with their model predicting $2.97 billion. Erleada's consensus is $691.6 million, with their model predicting $682.5 million.
In other products, Invega Sustenna and Uptravi could grow, and new medicines such as Carvykti, Tecvayli, Talvey, and Spravato are likely to contribute to top-line growth.
JNJ Key Financial Metrics
JNJ stock has shown downside pressure of 4.4% year-to-date, lagging the industry's 24% increase. Johnson and Johnson stock has also underperformed the S&P 500 and the sector.
JNJ's current forward P/E ratio is 14.02, which is lower than the industry average of 20.72. From a valuation perspective, the company looks attractive as the current trading level approaches the 52-week low.
